Jana Barinoff

2.3k total citations
49 papers, 976 citations indexed

About

Jana Barinoff is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Jana Barinoff has authored 49 papers receiving a total of 976 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Oncology, 23 papers in Cancer Research and 17 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Jana Barinoff's work include Breast Cancer Treatment Studies (18 papers), HER2/EGFR in Cancer Research (15 papers) and Advanced Breast Cancer Therapies (10 papers). Jana Barinoff is often cited by papers focused on Breast Cancer Treatment Studies (18 papers), HER2/EGFR in Cancer Research (15 papers) and Advanced Breast Cancer Therapies (10 papers). Jana Barinoff collaborates with scholars based in Germany, Switzerland and United States. Jana Barinoff's co-authors include Sibylle Loibl, Andreas du Bois, Florian Heitz, Gϋnter von Minckwitz, Philipp Harter, Alexander Traut, Jalid Sehouli, Marc Thill, Marcus Schmidt and Christoph Mundhenke and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Jana Barinoff

45 papers receiving 950 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jana Barinoff Germany 18 593 333 269 164 159 49 976
R. Largillier France 14 940 1.6× 527 1.6× 334 1.2× 198 1.2× 162 1.0× 47 1.5k
Holm Eggemann Germany 22 694 1.2× 651 2.0× 238 0.9× 145 0.9× 231 1.5× 76 1.6k
Eleni Timotheadou Greece 17 616 1.0× 201 0.6× 222 0.8× 76 0.5× 303 1.9× 76 1.0k
Saverio Danese Italy 16 408 0.7× 199 0.6× 114 0.4× 75 0.5× 228 1.4× 31 880
Casey W. Williamson United States 13 376 0.6× 184 0.6× 204 0.8× 94 0.6× 301 1.9× 30 926
Guillermo Villacampa Spain 14 587 1.0× 264 0.8× 327 1.2× 167 1.0× 226 1.4× 90 1.1k
Yu-Nien Sun United States 10 566 1.0× 196 0.6× 332 1.2× 105 0.6× 528 3.3× 12 1.4k
N.P. Koper Netherlands 12 583 1.0× 115 0.3× 176 0.7× 351 2.1× 109 0.7× 20 1.0k
S.H. Goey Netherlands 20 758 1.3× 91 0.3× 259 1.0× 209 1.3× 272 1.7× 31 1.2k
Joshua Chaim United States 14 458 0.8× 287 0.9× 732 2.7× 311 1.9× 408 2.6× 39 1.3k

Countries citing papers authored by Jana Barinoff

Since Specialization
Citations

This map shows the geographic impact of Jana Barinoff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jana Barinoff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jana Barinoff more than expected).

Fields of papers citing papers by Jana Barinoff

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jana Barinoff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jana Barinoff. The network helps show where Jana Barinoff may publish in the future.

Co-authorship network of co-authors of Jana Barinoff

This figure shows the co-authorship network connecting the top 25 collaborators of Jana Barinoff. A scholar is included among the top collaborators of Jana Barinoff based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jana Barinoff. Jana Barinoff is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Leichsenring, Jonas, Christine Solbach, Thomas Karn, et al.. (2022). EVI1 expression in early-stage breast cancer patients treated with neoadjuvant chemotherapy. BMC Cancer. 22(1). 1040–1040.
2.
3.
Plaikner, Andrea, Achim Schneider, Giovanni Favero, et al.. (2020). Comparison of surgical and pathological parameters after laparoscopic transperitoneal pelvic/para-aortic lymphadenectomies. International Journal of Gynecological Cancer. 30(11). 1798–1802. 1 indexed citations
4.
Buttmann‐Schweiger, Nina, Jana Barinoff, Annika Waldmann, Benjamin Barnes, & Klaus Kraywinkel. (2019). Epidemiologie der Krebserkrankungen von Vulva und Vagina in Deutschland. Der Onkologe. 25(5). 396–403. 1 indexed citations
5.
Jöhrens, Korinna, et al.. (2018). Mesothelin as a target for cervical cancer therapy. Archives of Gynecology and Obstetrics. 299(1). 211–216. 15 indexed citations
6.
Michiels, Stefan, Lina Pugliano, Sophie Marguet, et al.. (2016). Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer. Annals of Oncology. 27(6). 1029–1034. 31 indexed citations
7.
8.
Hg, Schnürch, S. Ackermann, Céline D. Alt, et al.. (2016). Diagnosis, Therapy and Follow-up Care of Vulvar Cancer and its Precursors. Guideline of the DGGG and DKG (S2k-Level, AWMF Registry Number 015/059, November 2015. Geburtshilfe und Frauenheilkunde. 76(10). 1035–1049. 44 indexed citations
9.
Harbeck, Nadia, Elke Jäger, Marcus Schmidt, et al.. (2016). A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study. Breast Cancer Research and Treatment. 161(1). 63–72. 33 indexed citations
10.
Thill, Marc, Kristin Baumann, & Jana Barinoff. (2014). Intraoperative assessment of margins in breast conservative surgery—still in use?. Journal of Surgical Oncology. 110(1). 15–20. 34 indexed citations
11.
Denkert, Carsten, Sibylle Loibl, Berit Müller, et al.. (2013). Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial. Annals of Oncology. 24(11). 2786–2793. 172 indexed citations
12.
Yang, James Chih‐Hsin, Noemı́ Reguart, Jana Barinoff, et al.. (2013). Diarrhea associated with afatinib: an oral ErbB family blocker. Expert Review of Anticancer Therapy. 13(6). 729–736. 88 indexed citations
13.
Heitz, Florian, Jana Barinoff, Rita Hils, et al.. (2013). Differences in the Receptor Status between Primary and Recurrent Breast Cancer - The Frequency of and the Reasons for Discordance. Oncology. 84(6). 319–325. 18 indexed citations
14.
Barinoff, Jana, Alexander Traut, Dirk Bauerschlag, et al.. (2013). Chemotherapy for 70-Year-Old Women with Breast Cancer in Germany: A Survey by the German Breast Group. Geburtshilfe und Frauenheilkunde. 73(5). 433–439. 3 indexed citations
15.
Heitz, Florian, Philipp Harter, Jana Barinoff, et al.. (2012). Bevacizumab in the Treatment of Ovarian Cancer. Advances in Therapy. 29(9). 723–735. 32 indexed citations
16.
Heitz, Florian, Andreas du Bois, Justine Rochon, et al.. (2012). Requirements to Assess Feasibility of Phase 0 Trials during Major Abdominal Surgery: Variability of PARP Activity. Clinical Cancer Research. 18(9). 2632–2637. 5 indexed citations
17.
Minckwitz, Gϋnter von, Kathrin Schwedler, Marcus Schmidt, et al.. (2011). Trastuzumab beyond progression: Overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer. European Journal of Cancer. 47(15). 2273–2281. 141 indexed citations
18.
Heidecke, Harald, et al.. (2011). In vitro vascular tube formation testing as a tool for treatment individualisation in patients with cervical cancer.. PubMed. 31(8). 2609–15. 5 indexed citations
19.
Witzel, Isabell, Sibylle Loibl, G von Minckwitz, et al.. (2010). Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial. Breast Cancer Research and Treatment. 123(2). 437–445. 37 indexed citations
20.
Heitz, Florian, Justine Rochon, Philipp Harter, et al.. (2010). Cerebral metastases in metastatic breast cancer: disease-specific risk factors and survival. Annals of Oncology. 22(7). 1571–1581. 39 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by R. Largillier Breakdown of academic impact, for papers by Holm Eggemann Breakdown of academic impact, for papers by Eleni Timotheadou Breakdown of academic impact, for papers by Saverio Danese Breakdown of academic impact, for papers by Casey W. Williamson Breakdown of academic impact, for papers by Guillermo Villacampa Breakdown of academic impact, for papers by Yu-Nien Sun Breakdown of academic impact, for papers by N.P. Koper Breakdown of academic impact, for papers by S.H. Goey Breakdown of academic impact, for papers by Joshua Chaim
Rankless by CCL
2026